How Repurposed Drugs Could Save Your Life When Standard Medicine Fails

This episode features Dr. David Fajgenbaum's remarkable journey from terminal patient to pioneering researcher in drug repurposing. Facing death from Castleman disease after exhausting all standard treatments, Fajgenbaum discovered that sirolimus (rapamycin), originally an immunosuppressant, could treat his condition by targeting specific inflammatory pathways. This personal breakthrough led him to found Every Cure, an organization systematically identifying how existing drugs can treat diseases they weren't designed for.

Fajgenbaum reveals surprising examples of drug repurposing with longevity implications. Aspirin reduces colorectal cancer risk in patients with specific genetic mutations, while low-dose colchicine significantly decreases cardiovascular events after heart attacks. Lidocaine used during breast cancer surgery may prevent metastasis, and various compounds show promise for preventive health applications. The discussion explores how pharmaceutical companies lack financial incentives to pursue new uses for off-patent drugs, creating gaps in medical knowledge.

The episode provides practical guidance for patients seeking treatment options beyond standard care. Fajgenbaum recommends consulting disease-specific organizations, using reliable medical databases, and asking physicians targeted questions about alternative treatments. He emphasizes the importance of hope combined with action, describing his 'hope-action-impact circuit' that drives both personal resilience and scientific progress.

Key insights include how AI and integrated medical databases can identify novel drug-disease connections, the role of stress and personality types in autoimmune conditions, and emerging applications of compounds like GLP-1 agonists beyond diabetes treatment. Fajgenbaum's work suggests thousands of life-saving treatments may already exist in our medicine cabinets, waiting to be discovered through systematic research and clinical investigation.